Neoleukin Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Neoleukin Therapeutics (NASDAQ: NLTX) plans to participate in two upcoming investor conferences. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 16, 2021, from 3:20 to 3:50 p.m. EST, featuring a fireside chat format. Following that, the Piper Sandler 33rd Annual Virtual Healthcare Conference will take place on November 22, 2021, with sessions available on-demand from 10:00 a.m. EST. Presentations will be accessible on Neoleukin's website, and archived replays will be available for at least 30 days post-event.

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in two upcoming investor conferences.

Presentation Details:

Event: Stifel 2021 Virtual Healthcare Conference
Date: Tuesday, November 16, 2021
Time: 3:20 to 3:50 p.m. EST
Format: Fireside chat
          
Event: Piper Sandler 33^rd Annual Virtual Healthcare Conference
Date: Monday, November 22, 2021
Time: Available on-demand starting 10:00 a.m. EST
Format: Fireside chat

The presentations will be available from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.  Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Safe Harbor / Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the company’s de novo protein design technology, the results of the clinical trial for NL-201, and planned clinical and development activities and timelines. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company’s cash forecasts, the company’s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company’s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin’s business and its financial results are detailed under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

FAQ

When will Neoleukin Therapeutics participate in the Stifel 2021 Virtual Healthcare Conference?

Neoleukin Therapeutics will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, from 3:20 to 3:50 p.m. EST.

What is the date and format of Neoleukin's participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference?

Neoleukin will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, with sessions available on-demand starting at 10:00 a.m. EST.

How can I access the presentations from Neoleukin's investor conferences?

Presentations from Neoleukin's investor conferences can be accessed through the investor section of their website, and archived replays will be available for at least 30 days after the events.

What is the main focus of Neoleukin Therapeutics?

Neoleukin Therapeutics focuses on creating next-generation immunotherapies for cancer, inflammation, and autoimmunity using advanced de novo protein design technology.

What is NL-201, Neoleukin's lead product candidate?

NL-201 is Neoleukin's lead product candidate, designed as a combined IL-2 and IL-15 agonist aimed at improving tolerability and activity in therapeutics.